Want to see JP:4579 full AI Analyst Report?
RaQualia Pharma Inc. (4579) Stock Statistics & Valuation Metrics
Total Valuation
RaQualia Pharma Inc. has a market cap or net worth of JPY 15.36B. The enterprise value is JPY 10.30B.
- Market Cap
- JPY 15.36B
- Enterprise Value
- JPY 10.30B
Share Statistics
RaQualia Pharma Inc. has 26,031,412 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 26,031,412
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
RaQualia Pharma Inc.’s return on equity (ROE) is 0.04 and return on invested capital (ROIC) is 3.07%.
- Return on Equity (ROE)
- 0.04
- Return on Assets (ROA)
- 0.03
- Return on Invested Capital (ROIC)
- 3.07%
- Return on Capital Employed (ROCE)
- 0.05
- Revenue Per Employee
- 46.82M
- Profits Per Employee
- 3.21M
- Employee Count
- 85
- Asset Turnover
- 0.38
- Inventory Turnover
- 4.46
Valuation Ratios
The current PE Ratio of RaQualia Pharma Inc. is 63.46. RaQualia Pharma Inc.’s PEG ratio is 3.10.
- PE Ratio
- 63.46
- PS Ratio
- 3.79
- PB Ratio
- 1.89
- Price to FCF
- 32.23
- Price to Operating Cash Flow
- 29.59
- PEG Ratio
- 3.10
Income Statement
In the last 12 months, RaQualia Pharma Inc. had revenue of 3.98B and earned 273.12M in profits. Earnings per share was 11.53.
- Revenue
- 3.98B
- Gross Profit
- 3.27B
- Operating Income
- 483.72M
- Pretax Income
- 437.95M
- Net Income
- 273.12M
- EBITDA
- 985.17M
- Earnings Per Share (EPS)
- 11.53
Cash Flow
In the last 12 months, operating cash flow was 499.45M and capital expenditures -40.66M, giving a free cash flow of 458.80M billion.
- Operating Cash Flow
- 499.45M
- Free Cash Flow
- 458.80M
- Free Cash Flow per Share
- 17.63
Dividends & Yields
RaQualia Pharma Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 2.88%
- Earnings Yield
- 1.01%
Stock Price Statistics
- Beta
- 1.00
- 52-Week Price Change
- 19.53%
- 50-Day Moving Average
- 594.88
- 200-Day Moving Average
- 675.34
- Relative Strength Index (RSI)
- 44.25
- Average Volume (3m)
- 150.54K
Important Dates
RaQualia Pharma Inc. upcoming earnings date is Nov 13, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 14, 2026
- Next Earnings Date
- Nov 13, 2026
- Ex-Dividend Date
- ―
Financial Position
RaQualia Pharma Inc. as a current ratio of 4.46, with Debt / Equity ratio of 42.08%
- Current Ratio
- 4.46
- Quick Ratio
- 4.33
- Debt to Market Cap
- 0.11
- Net Debt to EBITDA
- -0.34
- Interest Coverage Ratio
- 8.19
Taxes
In the past 12 months, RaQualia Pharma Inc. has paid 164.83M in taxes.
- Income Tax
- 164.83M
- Effective Tax Rate
- 0.38
Enterprise Valuation
RaQualia Pharma Inc. EV to EBITDA ratio is 16.58, with an EV/FCF ratio of 30.61.
- EV to Sales
- 3.60
- EV to EBITDA
- 16.58
- EV to Free Cash Flow
- 30.61
- EV to Operating Cash Flow
- 28.11
Balance Sheet
RaQualia Pharma Inc. has JPY 4.70B in cash and marketable securities with JPY 2.69B in debt, giving a net cash position of JPY 2.01B billion.
- Cash & Marketable Securities
- JPY 4.70B
- Total Debt
- JPY 2.69B
- Net Cash
- JPY 2.01B
- Net Cash Per Share
- JPY 77.23
- Tangible Book Value Per Share
- JPY 163.08
Margins
Gross margin is 79.46%, with operating margin of 8.60%, and net profit margin of 4.13%.
- Gross Margin
- 79.46%
- Operating Margin
- 8.60%
- Pretax Margin
- 10.34%
- Net Profit Margin
- 4.13%
- EBITDA Margin
- 21.72%
- EBIT Margin
- 9.49%
Analyst Forecast
The average price target for RaQualia Pharma Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 20.64%
- EPS Growth Forecast
- ―
Scores
- Smart Score
- ―
- AI Score
- 58
